Skip to content
Peptigraph home
Shop Peptides50% off*

What phase is retatrutide in?

Retatrutide is in phase 3: the TRIUMPH programme consists of four phase 3 randomized trials of weekly subcutaneous retatrutide against placebo in over 5800 participants.

GLP-1 / GIP / glucagon triple agonistUpdated

Short answer

Retatrutide is in phase 3: the TRIUMPH programme consists of four phase 3 randomized trials of weekly subcutaneous retatrutide against placebo in over 5800 participants.[1]

Which phase 3 trials have reported

TRIUMPH-1, a phase 3 trial in adults with obesity without diabetes, assigned participants to 4, 9 or 12 mg or placebo weekly for 80 weeks.[2]

A phase 3 trial in type 2 diabetes describes retatrutide as under clinical development for diabetes, obesity and related complications.[3]

Not every study is phase 3: TRANSCEND-CKD is a phase 2b mechanistic trial in chronic kidney disease.[4]

Drugs@FDA still returns no match for retatrutide, so phase 3 has not yet produced an approved product in that database.[5]

More questions on Retatrutide

Can retatrutide cause cancer?Can retatrutide cause high blood pressure?Can retatrutide cause joint pain?Can retatrutide cause pancreatitis?Can women take retatrutide?Can you build muscle on retatrutide?

More on Retatrutide

Retatrutide overview

Sources

  1. 1Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.Diabetes, obesity & metabolism · 2026PMID 41090431Accessed 2 Oct 2026
  2. 2Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.The New England journal of medicine · 2026PMID 42814954Accessed 2 Oct 2026
  3. 3Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 42250575Accessed 2 Oct 2026
  4. 4Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026PMID 41160422Accessed 2 Oct 2026
  5. 5Drugs@FDA (openFDA) search: active ingredient "retatrutide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.